Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer

NCT03539328 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

138

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Gemcitabine
DRUG: Paclitaxel
DRUG: Liposomal Doxorubicin

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano